Emphysema: time to say farewell to therapeutic nihilism

Zaid Zoumot, Simon Jordan, Nicholas S Hopkinson

It is an interesting time for the management of emphysema. In this condition, destruction of lung parenchyma associated with reduced elastic recoil and dynamic airways closure produce gas trapping and increased operating lung volumes, leading to breathlessness and exercise limitation. It has historically been defined as an irreversible process, which has led to a degree of therapeutic nihilism. One manifestation of this has been the curious neglect of lung volume reduction surgery (LVRS). Clinical guidelines,1 reflecting trial evidence,2 recommend consideration of LVRS in selected patients with upper lobe predominant emphysema and poor exercise capacity, the phenotype where surgery has been shown to produce a survival benefit. Modern surgical techniques, unilateral treatment and improved post-operative care and patient selection mean that LVRS is also associated with lower morbidity and mortality than data published at the turn of the century had suggested.3 4 with one recent case series reporting zero 90-day mortality following unilateral surgery.5

Nevertheless, little effort seems to be going into identifying this patient population and LVRS remains vastly underused with just 90 procedures taking place in the UK in 2010–2011. A partial explanation for this may be found in a recent survey of British Thoracic Society members that revealed that a significant proportion overestimated the morbidity and mortality associated with LVRS.6

Only 30% had access to a dedicated chronic obstructive pulmonary disease (COPD) multidisciplinary meeting to review patients, and there was no consensus as to the correct strategy to adopt to identify appropriate patients.

Over the last decade, bronchoscopic approaches for lung volume reduction in emphysema have proliferated. These include one-way endobronchial valves to induce lobar collapse,7–10 airway bypass approaches to create low-resistant extra-anatomical pathways that allow trapped gas to escape,11 12 lung volume reduction coils (LVRC) that re-tension the lung preventing dynamic airway collapse,13 and techniques intended to reduce lung volumes by scarring either through bronchial thermal vapour ablation (‘steam’)14 or the use of biological agents.15 16 These approaches offer the potential to achieve lung volume reduction, improving symptoms and even prolonging survival17 while avoiding the problems inherent in an invasive surgical intervention. However, for each approach issues around the magnitude and duration of effect, optimum patient selection, safety profile and cost need to be addressed through properly conducted clinical trials with robust endpoints.

Deslee and colleagues present 6-month and 12-month data from a multicentre, single-arm study of staged, bilateral LVRC treatment in patients with severe emphysema.17 They report improvements in St George’s Respiratory Questionnaire (SGRQ) scores of −11.1 ± 13.3 points 12 months following therapy as compared with baseline, with persistent benefits in 6 minute walking distance (6MWD), forced expiratory flow in the 1st second (FEV1) and residual volume (RV) exceeding accepted minimal clinically important differences. These data are encouraging and add to existing data from short-term controlled trials,13 but the limitations of this study merit some consideration when considering the general issues for bronchoscopic therapies outlined above. It was uncontrolled and unblinded, with only roughly half the cohort followed up beyond 6 months and the primary outcome was a quality of life score. This is questionable in a single-arm study without a sham procedure, given the powerful placebo effect seen with this sort of intervention. Nevertheless, the sustained improvement in lung volumes seems to indicate a persistent physiological effect. Longer-term follow-up in randomised controlled studies will be needed to be able to comment definitively on sustained benefits of LVRC. The RENEW trial (clinicaltrials.gov NCT01608490), which is currently underway with a primary end-point of 6MWD 12 months post-recruitment will address this.

The authors do not clarify what the distribution of recruitment among the 11 participating centres was or their prior experience with the technique. Two patients recruited for bilateral coil treatment were then thought to be unsuitable for contralateral treatment on a ‘second look’ at their imaging. In addition, the trial was meant to enrol only patients with heterogeneous disease, yet 13 and 17 of 33 patients reaching 12 months’ follow-up were deemed ‘homogeneous’ on visual and computerised scoring, respectively. The authors propose that homogeneous emphysema responds to treatment with LVRC to a similar extent to heterogeneous disease, but this must be considered hypothesis generating only and to some extent seems to reflect a failure in the application of the initial protocol. The problem of recruiting patients for lung volume reduction trials who on post hoc analysis do not fulfil entry criteria is not unique to this study.11

Safety is another key issue. It has been assumed that bronchoscopic lung volume reduction is safer and cheaper than LVRS. Pneumothorax occurred within 30 days in 4 of 135 procedures (3.5%), with a per patient rate of 11.7% (7/60) during the follow-up period. Pneumothorax following bronchoscopic lung volume reduction procedures can be delayed and can be fatal. This means that as well as formal safety criteria around lung function and exercise capacity a general clinical assessment of the patient’s likely ability to cope with this complication needs to be made. In practice, relatively few people judged ‘too unwell for LVRS’ may be eligible for a bronchoscopic approach. All patients treated as part of this trial had general anaesthesia in an operating theatre, but it should be noted that these procedures can be performed safely in the bronchoscopy suite under sedation.13

A review article written a decade ago posed the question ‘Endobronchial lung volume reduction, a myth, or a marvel?’12 The proliferation of techniques and publications mean that these approaches can no longer be considered mythical, but nor any longer are they ‘a marvel’. Rather, they must be considered as techniques with a developing evidence base and varying response rates and complications where a case must be made that they represent good value, considered in terms of the resources employed and the health outcomes obtained. The London Respiratory Network has produced a value pyramid for COPD interventions19 (figure 1), but it remains to be established where each bronchoscopic approach will sit. LVRS was estimated as costing $40,000 per quality adjusted life year (QALY) based on

NIHR Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, London, UK

Correspondence to Dr Nicholas Hopkinson, NIHR Respiratory Biomedical Research Unit, Royal Brompton and Harefield NHS Foundation Trust and Imperial College London, Royal Brompton Hospital, Fulham Rd, London SW3 6NP, UK; n.hopkinson@ic.ac.uk
The US National Emphysema Treatment Trial (NETT), but the likely true figure is considerably lower, given improvements in technique with reduced mortality, morbidity and length of stay. The cost of LVRCs is at present high with the list price of the devices themselves significantly exceeding the national LVRS tariff in the UK. As with LVRS, the response rates for bronchoscopic techniques are crucially dependent on appropriate patient selection, with different criteria for different devices. This takes us back to the need to develop a multi-disciplinary team (MDT) approach for emphysema (table 1). Given trial data indicating improved survival, a failure to offer LVRS to appropriate patients with COPD and by extension a failure to make the effort to identify them seems to us to border on negligence. The development of a network of emphysema MDTs should also facilitate the more rapid delivery of trials to investigate the efficacy of experimental treatments and ensure that appropriate criteria are used to select individuals for more established interventions such as endobronchial valves to ensure a high responder rate and the best value for the healthcare system.

### Table 1  Approach to selecting patients with emphysema for a possible lung volume reduction procedure

<table>
<thead>
<tr>
<th>Considerations</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Are they too well to consider intervention?</td>
<td>Lung function, exercise capacity, prognosis, Medical Research Council dyspnoea score &lt;3</td>
</tr>
<tr>
<td>Are they too unwell for intervention to be safe?</td>
<td>Lung function, frailty, exercise capacity &lt;100 m, oxygen dependence</td>
</tr>
<tr>
<td>Is treatment optimal?</td>
<td>Smoking cessation, pulmonary rehabilitation, flu vaccination, inhaled and oral medication</td>
</tr>
<tr>
<td>Is their lung function likely to rule out a procedure on safety grounds?</td>
<td>All three of FEV1, TLco and Kco &lt;20% predicted</td>
</tr>
<tr>
<td>Do they have comorbidities that limit likely benefit or increase risk?</td>
<td>For example, pulmonary hypertension, unstable cardiac disease, malignancy, cerebrovascular disease. Ongoing smoking (possibility of intervention may help to promote quit attempts)</td>
</tr>
<tr>
<td>Have they ever had a CT thorax and if so has it been reported in terms of emphysema pattern?</td>
<td>Review existing CT’s or obtain a CT if a potential candidate as above</td>
</tr>
</tbody>
</table>

Review CT and lung function in multi-disciplinary teams including respiratory physician, radiologist, thoracic surgeon. Further investigations including echocardiogram, lung perfusion scan and a formal field exercise test (shuttle walk or 6 minute walk test) may be indicated.

---

**Figure 1** The pyramid of value for COPD interventions developed by the London Respiratory Network with The London School of Economics (modified from 19) gives estimates of cost per quality adjusted life year gained. LABA long-acting β2 agonist; QALY, quality adjusted life year.

---

**Table 1** Approach to selecting patients with emphysema for a possible lung volume reduction procedure

<table>
<thead>
<tr>
<th>Considerations</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Are they too well to consider intervention?</td>
<td>Lung function, exercise capacity, prognosis, Medical Research Council dyspnoea score &lt;3</td>
</tr>
<tr>
<td>Are they too unwell for intervention to be safe?</td>
<td>Lung function, frailty, exercise capacity &lt;100 m, oxygen dependence</td>
</tr>
<tr>
<td>Is treatment optimal?</td>
<td>Smoking cessation, pulmonary rehabilitation, flu vaccination, inhaled and oral medication</td>
</tr>
<tr>
<td>Is their lung function likely to rule out a procedure on safety grounds?</td>
<td>All three of FEV1, TLco and Kco &lt;20% predicted</td>
</tr>
<tr>
<td>Do they have comorbidities that limit likely benefit or increase risk?</td>
<td>For example, pulmonary hypertension, unstable cardiac disease, malignancy, cerebrovascular disease. Ongoing smoking (possibility of intervention may help to promote quit attempts)</td>
</tr>
<tr>
<td>Have they ever had a CT thorax and if so has it been reported in terms of emphysema pattern?</td>
<td>Review existing CT’s or obtain a CT if a potential candidate as above</td>
</tr>
</tbody>
</table>

Review CT and lung function in multi-disciplinary teams including respiratory physician, radiologist, thoracic surgeon. Further investigations including echocardiogram, lung perfusion scan and a formal field exercise test (shuttle walk or 6 minute walk test) may be indicated.

---

**Figure 1** The pyramid of value for COPD interventions developed by the London Respiratory Network with The London School of Economics (modified from 19) gives estimates of cost per quality adjusted life year gained. LABA long-acting β2 agonist; QALY, quality adjusted life year.
To cite Zoumot Z, Jordan S, Hopkinson NS. Thorax 2014;69:973–975. doi:10.1136/thoraxjnl-2014-205667

REFERENCES


